CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma

por Alon, Michal, Arafeh, Rand, Lee, Joo Sang, Madan, Sanna, Kalaora, Shelly, Nagler, Adi, Abgarian, Tereza, Greenberg, Polina, Ruppin, Eytan, Samuels, Yardena
Publicado 2018

Correction: CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma

por Alon, Michal, Arafeh, Rand, Lee, Joo Sang, Madan, Sanna, Kalaora, Shelly, Nagler, Adi, Abgarian, Tereza, Greenberg, Polina, Ruppin, Eytan, Samuels, Yardena
Publicado 2019

A genome‐wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS‐mutant melanoma

por Nagler, Adi, Vredevoogd, David W., Alon, Michal, Cheng, Phil F., Trabish, Sophie, Kalaora, Shelly, Arafeh, Rand, Goldin, Victoria, Levesque, Mitchell P., Peeper, Daniel S., Samuels, Yardena
Publicado 2019

Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics

por Nagler, Adi, Kalaora, Shelly, Barbolin, Chaya, Gangaev, Anastasia, Ketelaars, Steven L.C., Alon, Michal, Pai, Joy, Benedek, Gil, Yahalom-Ronen, Yfat, Erez, Noam, Greenberg, Polina, Yagel, Gal, Peri, Aviyah, Levin, Yishai, Satpathy, Ansuman T., Bar-Haim, Erez, Paran, Nir, Kvistborg, Pia, Samuels, Yardena
Publicado 2021